Catalog No. | HP158016 |
---|---|
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Host species | Humanized |
Isotype | (scFv-kappa-heavy) -h- CH3 |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | T-cell surface glycoprotein CD8 alpha chain, CD8a, T-lymphocyte differentiation antigen T8/Leu-2, MAL, CD8A |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Purified by ion exchange chromatography. |
Accession | P01732 |
Form | Liquid |
Storage buffer | 0.01M PBS,pH7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names | 89Zr-IAB22M2C,IAB22M2C,89Zr-Df-IAB22M2C,CAS:2611099-93-3 |
Background | Crefmirlimab is a humanized CD8 specific minibody. The minibody (Mb) maintains the specificity of full-length antibodies but has no immune effector functions and is biologically inert. |
Note | For research use only. Not for use in clinical or therapeutic applications. |
Detects CD8A in indirect ELISAs.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France